Aclaris therapeutics initiates phase 1a/1b program for its novel bispecific antibody ati-052

- potential best-in-class bispecific antibody ati-052 targets both thymic stromal lymphopoietin (tslp) and interleukin-4 receptor (il-4r) - wayne, pa., june 23, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled phase 1a/1b program for ati-052, the company's potential best-in-class investigational bispecific anti-tslp/il-4r antibody.
ACRS Ratings Summary
ACRS Quant Ranking